ema retatrutide approval Is Approved in Other Countries? (2026) There are rumors that Trump

Description

However, it should be noted that not all individual SGLT2is and GLP-1 RAs are equal regarding kidney, cardiovascular, and metabolic outcomes

The disadvantage is that one-size-fits-all formulations cannot account for individual deficiency patterns, which vary significantly based on baseline nutritional status, specific medication, dose, and diet quality

In this respect, GLP-1 receptor agonists represent disease-modifying agents with implications that extend well beyond the management of weight and glycaemia

(And even if they were approved, pharmaceutical companies would shy away from them for fear of being undercut by compounding pharmacies.) If companies can sell them and make lots of money without having to prove that they do what theyre claimed to do, why wouldnt they? Zettler points out